Related Experiment Video
Updated: Dec 20, 2025

11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
8.3K
Prostatic Artery Embolization for Benign Prostatic Hyperplasia Treatment: A Russian Multicenter Study in More Than
Armais Kamalov1,2, Sergei Kapranov3, Alexander Neymark4
1Urology and Andrology Department, Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia.
American Journal of Men'S Health
|June 4, 2020
Summary
Superselective prostatic artery embolization (PAE), specifically the PErFecTED technique, significantly improves symptoms and quality of life for benign prostatic hyperplasia (BPH) patients over 24 months.
Area of Science:
- Urology
- Interventional Radiology
- Geriatric Medicine
Background:
- Benign prostatic hyperplasia (BPH) is a prevalent genitourinary condition affecting aging men.
- Traditional transurethral resection of the prostate (TURP) carries risks of significant complications.
- Minimally invasive alternatives are sought to manage BPH effectively and safely.
Purpose of the Study:
- To evaluate the efficacy and safety of the PErFecTED technique for superselective prostatic artery embolization (PAE) in BPH patients.
- To assess long-term outcomes of PAE in terms of symptom improvement and quality of life.
Main Methods:
- Retrospective analysis of data from 1,015 BPH patients undergoing endovascular PAE using the PErFecTED technique.
- Assessment of International Prostate Symptom Score (IPSS) and Quality of Life (QoL) scores over a 24-month follow-up period.
Main Results:
- The PErFecTED technique demonstrated significant benefits for BPH patients over 24 months.
- Both IPSS and QoL scores improved approximately threefold in the PErFecTED group.
- Symptom improvement and quality of life benefits remained stable throughout the observation period.
Conclusions:
- The PErFecTED technique is an effective minimally invasive treatment for BPH, offering sustained symptom relief and improved quality of life.
- While beneficial, the PAE technique requires further refinement to mitigate the risk of postembolization syndrome.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
368
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
368
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
340
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
340

